Abstract 4346: Improved pharmacokinetic properties of the purified S-enantiomer of the alkylphospholipid Edelfosine compared to the racemic mixture: Potential orally available novel anticancer agent active against pancreatic cancer - KIVIRID

Abstract 4346: Improved pharmacokinetic properties of the purified S-enantiomer of the alkylphospholipid Edelfosine compared to the racemic mixture: Potential orally available novel anticancer agent active against pancreatic cancer

Authors: Michael Ahrweiler, Wolfgang Meyer, Daniel Perrissoud, Axel Zander

Published: 2025-04-21

DOI: 10.1158/1538-7445.am2025-4346

Source: Full article

Abstract

Abstract